Who owns Rhythm Pharmaceuticals (RYTM)? Superinvestor holders
4 superinvestors of the 157 tracked here hold Rhythm Pharmaceuticals (RYTM) in their latest 13F filing, with $1.7B between them. Peter Kolchinsky gives it the most weight: 6.43% of the reported portfolio. In their latest reported quarter, Stanley Druckenmiller opened a position; Primecap team reduced.
Key facts
- Superinvestors holding it
- 4 of 157
- Biggest holder
- Peter Kolchinsky, $740.2M
- Largest weight
- Peter Kolchinsky, 6.43%of their portfolio
- Combined value
- $1.7B
- Bought last quarter
- 1
- Sold last quarter
- 1
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Peter KolchinskyRA Capital Management | 6.43% | $740.2M | 6.67M | No change | 0 | Q2 2026 |
| 2 | Julian and Felix BakerBaker Bros. Advisors | 3.12% | $622.3M | 5.6M | No change | 0 | Q2 2026 |
| 3 | Stanley DruckenmillerDuquesne Family Office | 0.52% | $22.6M | 203.62K | New | +203.62K | Q2 2026 |
| 4 | Primecap teamPrimecap Management | 0.18% | $291.8M | 3.06M | ▼ Reduced 3.3% | −104.57K | Q3 2026 |
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 1 | 3.06M | $291.8M | 0 | 1 |
| Q2 2026 | 157 | 4 | 15.64M | $1.7B | 1 | 1 |
| Q1 2026 | 157 | 3 | 15.69M | $1.4B | 0 | 1 |
| Q4 2025 | 157 | 3 | 15.75M | $1.7B | 1 | 2 |
| Q3 2025 | 157 | 4 | 16.57M | $1.7B | 1 | 1 |
| Q2 2025 | 157 | 4 | 17.06M | $1.1B | 1 | 2 |
| Q1 2025 | 156 | 4 | 18.29M | $969M | 0 | 3 |
| Q4 2024 | 156 | 4 | 19.91M | $1.1B | 0 | 2 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Primecap team | 3.06M | 3.17M | 3.42M | 3.48M | 4.26M | 4.88M | 5.79M | 6.57M |
| Peter Kolchinsky | · | 6.67M | 6.67M | 6.67M | 5.68M | 5.56M | 6.08M | 6.08M |
| Julian and Felix Baker | · | 5.6M | 5.6M | 5.6M | 5.6M | 5.6M | 5.6M | 6.08M |
| Stanley Druckenmiller | · | 203.62K | — | — | — | — | — | — |
| Takis Sparaggis | — | — | — | — | 1.02M | 1.02M | 817.7K | 1.17M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own RYTM?
In their latest 13F filings: Peter Kolchinsky (6.43% of the portfolio, $740.2M), Julian and Felix Baker (3.12% of the portfolio, $622.3M), Stanley Druckenmiller (0.52% of the portfolio, $22.6M), Primecap team (0.18% of the portfolio, $291.8M).
Who bought RYTM last quarter?
Stanley Druckenmiller (new position). “Last quarter” is each investor's latest reported quarter.
Who sold RYTM last quarter?
Reduced: Primecap team (3.3% fewer shares).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Rhythm Pharmaceuticals (RYTM)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/RYTM/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to RYTM by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.